Alameh Mohamad-Gabriel, Weissman Drew, Pardi Norbert
Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Curr Top Microbiol Immunol. 2022;440:111-145. doi: 10.1007/82_2020_202.
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.
基于体外转录信使核糖核酸的传染病疫苗有潜力成功解决传统疫苗平台的许多弱点，例如疫苗保护效力不足和/或持久性不足、生产耗时且昂贵，以及在某些情况下存在安全问题。近期大量令人印象深刻的数据表明，信使核糖核酸疫苗具备成为一种可行的新型人类用疫苗所需的许多特性，这进一步增强了人们的乐观情绪。本综述简要描述了信使核糖核酸疫苗的类型，讨论了关于传染病信使核糖核酸疫苗最相关和最新的出版物，并强调了要将这种有前景的新型疫苗形式推向临床需要克服的障碍。
